[go: up one dir, main page]

AR046964A1 - Heterociclos azabiciclicos como moduladores de receptor canabinoide, composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades relacionadas con trastornos metabolicos y de la alimentacion. - Google Patents

Heterociclos azabiciclicos como moduladores de receptor canabinoide, composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades relacionadas con trastornos metabolicos y de la alimentacion.

Info

Publication number
AR046964A1
AR046964A1 ARP040104771A ARP040104771A AR046964A1 AR 046964 A1 AR046964 A1 AR 046964A1 AR P040104771 A ARP040104771 A AR P040104771A AR P040104771 A ARP040104771 A AR P040104771A AR 046964 A1 AR046964 A1 AR 046964A1
Authority
AR
Argentina
Prior art keywords
group
nr8s
heteroarylalkyl
cycloalkylalkyl
arylalkyl
Prior art date
Application number
ARP040104771A
Other languages
English (en)
Inventor
Guixue Yu
William R Ewing
Amarendra B Mikkilineni
Annapurna Pendri
Samuel W Gerritz
Gang Wu
Yanting Huang
Chongqing Sun
Natesan Murugesan
Zhengxiang Gu
Ying Wang
Stephen R Johnson
Ximao Wu
Philip M Sher
Bruce A Ellsworth
Doree F Sitkoff
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AR046964A1 publication Critical patent/AR046964A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)

Abstract

Compuestos de conformidad con la formula (1), composiciones farmacéuticas que comprenden al menos un compuesto de conformidad con la formula (1) y opcionalmente uno o más agentes terapéuticos para tratamiento de enfermedades relacionadas con trastornos metabolicos y de la alimentacion que usan los compuestos de conformidad con la formula (1) tanto solos como en combinacion con uno o más agentes terapéuticos. Reivindicacion 1: El compuesto de la formula (1) incluyendo todos los profármacos, sales y estereoisomeros farmacéuticamente aceptables, caracterizado porque: n es un enlace sencillo o un enlace doble; R1 es seleccionado del grupo que consiste de halogeno, ciano, alquilo, alquenilo, alquinilo, cicloalquilo, cicloalquilalquilo, heterociclilo, heterociclilalquilo, arilo, arilalquilo, heteroarilo, heteroarilalquilo, ariloxi, heteroariloxi, NR8R9, CO2R8, -CONR8R9, -OR8, NR8COR9, -NR8CONR8R9, -NR8CO2R9, -OCONR8R9, -NR8S(O)mR9, -NR8S(O)mNR8R9, -NR8S(O)mOR9 y -OS(O)mNR8R9; R2 es seleccionado del grupo que consiste de halogeno, ciano, alquilo, alquenilo, alquinilo, cicloalquilo, cicloalquilalquilo, heterociclilo, heterociclilalquilo, arilo, arilalquilo, heteroarilo, heteroarilalquilo, ariloxi, heteroariloxi, NR8R9, CO2R8, -CONR8R9, -OR8, -NR8COR9, -NR8CONR8R9, -NR8CO2R9, -OCONR8R9, -NR8S(O)mR9, -NR8S(O)mNR8R9, -NR8S(O)mOR9 y -OS(O)mNR8R9; R3 es seleccionado del grupo que consiste de alquilo, alquenilo, alquinilo, cicloalquilo, cicloalquilalquilo, heterociclilalquilo, arilalquilo y heteroarilalquilo; R6 es seleccionado del grupo que consiste de H, alquilo, cicloalquilo, heterociclilo, cicloalquilalquilo, heterocicloalquilo, arilo, heteroarilo, arilalquilo y heteroarilalquilo, en donde el grupo R6 tiene un peso molecular de menos de 200 unidades de masa atomica; R7 está ausente cuando n es un enlace doble; R7 es seleccionado del grupo que consiste de H, alquilo, cicloalquilo, heterociclilo, cicloalquilalquilo, heterocicloalquilo, arilo, heteroarilo, arilalquilo, heteroarilalquilo, COR8, -CO2R8, -CONR8R9 y S(O)mR8 cuando n es un enlace sencillo R8 y R9 son independientemente seleccionados del grupo que consiste de H, alquilo, arilo, arilalquilo, cicloalquilo, cicloalquilalquilo, heterociclilo, heterocicloalquilo, heteroarilo, y heteroarilalquilo; R8 y R9 al tomarse juntos puede opcionalmente formar un anillo heterociclilo de 4, 5, 6 o 7 miembros o un anillo heteroarilo de 5 o 6 miembros; y m es un entero de 1 o 2.
ARP040104771A 2003-12-19 2004-12-17 Heterociclos azabiciclicos como moduladores de receptor canabinoide, composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades relacionadas con trastornos metabolicos y de la alimentacion. AR046964A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US53145103P 2003-12-19 2003-12-19

Publications (1)

Publication Number Publication Date
AR046964A1 true AR046964A1 (es) 2006-01-04

Family

ID=34710226

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP040104771A AR046964A1 (es) 2003-12-19 2004-12-17 Heterociclos azabiciclicos como moduladores de receptor canabinoide, composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades relacionadas con trastornos metabolicos y de la alimentacion.
ARP040104772A AR047063A1 (es) 2003-12-19 2004-12-17 Heterociclos azabiciclicos como moduladores de receptor canabinoide

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP040104772A AR047063A1 (es) 2003-12-19 2004-12-17 Heterociclos azabiciclicos como moduladores de receptor canabinoide

Country Status (11)

Country Link
US (1) US7037910B2 (es)
EP (1) EP1699796A4 (es)
JP (1) JP2007514756A (es)
CN (2) CN1918165A (es)
AR (2) AR046964A1 (es)
IS (1) IS8501A (es)
NO (1) NO20062689L (es)
PE (2) PE20051047A1 (es)
TW (2) TW200528455A (es)
WO (1) WO2005061509A1 (es)
ZA (2) ZA200604645B (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100210590A1 (en) * 1995-09-27 2010-08-19 Northwestern University Compositions and treatments for seizure-related disorders
WO2003018563A1 (en) 2001-08-31 2003-03-06 Northwestern University Anti-inflammatory and protein kinase inhibitor composition and method of use
AU2004309368A1 (en) 2003-12-19 2005-07-14 Bristol-Myers Squibb Company Azabicyclic heterocycles as cannabinoid receptor modulators
US20060025448A1 (en) * 2004-07-22 2006-02-02 Cadila Healthcare Limited Hair growth stimulators
CA2589102C (en) * 2004-11-02 2013-08-13 Northwestern University Pyridazine compounds and methods for using the compounds to treat inflammatory diseases
CA2589106C (en) 2004-11-02 2015-07-21 Northwestern University Pyridazine compounds, compositions and methods and their use in treating inflammatory diseases
US7317012B2 (en) * 2005-06-17 2008-01-08 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoind-1 receptor modulators
RU2424242C2 (ru) * 2006-03-30 2011-07-20 Айрм Ллк Азолопиримидины в качестве ингибиторов активности каннабиноидного рецептора 1
CN101754762A (zh) 2006-04-28 2010-06-23 西北大学 用于治疗神经炎症性疾病的包含哒嗪化合物的制剂
CA2650711A1 (en) * 2006-04-28 2007-11-08 Northwestern University Compositions and treatments using pyridazine compounds and cholinesterase inhibitors
ATE448778T1 (de) * 2006-05-04 2009-12-15 Solvay Pharm Bv Muscarin-agonisten zur behandlung von impulskontrollstörungen
AU2007283113A1 (en) 2006-08-08 2008-02-14 Sanofi-Aventis Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use
US20160331729A9 (en) 2007-04-11 2016-11-17 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
US11241420B2 (en) 2007-04-11 2022-02-08 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
EP3788877B1 (en) * 2007-04-11 2024-08-07 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
CA2723689C (en) * 2008-05-05 2016-07-05 Ryan A. Shenvi Synthesis of (+) cortistatin a and related compounds
EP2310372B1 (en) 2008-07-09 2012-05-23 Sanofi Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
ES2443016T3 (es) 2009-08-26 2014-02-17 Sanofi Nuevos hidratos cristalinos de fluoroglicósidos heteroaromáticos, productos farmacéuticos que comprenden estos compuestos, y su empleo
FR2958850B1 (fr) * 2010-04-14 2012-07-06 Centre Nat Rech Scient Medicaments pour la prevention ou le traitement des addictions aux drogues
JP5934184B2 (ja) * 2010-04-20 2016-06-15 ウニヴェルシタ・デグリ・ストゥディ・ディ・ローマ・ラ・サピエンツァ ヒストンデメチラーゼｌｓｄ１及び／又はｌｓｄ２の阻害剤としてのトラニルシプロミン誘導体
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8846666B2 (en) 2011-03-08 2014-09-30 Sanofi Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2683700B1 (de) 2011-03-08 2015-02-18 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8809324B2 (en) 2011-03-08 2014-08-19 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
EP2683705B1 (de) 2011-03-08 2015-04-22 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8809325B2 (en) 2011-03-08 2014-08-19 Sanofi Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof
WO2012120057A1 (de) 2011-03-08 2012-09-13 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
JP5437525B1 (ja) 2012-12-28 2014-03-12 株式会社ナード研究所 チロシン誘導体およびチロシン誘導体の製造方法
CN103933569B (zh) * 2013-01-22 2017-01-11 复旦大学 一种抗肺癌药物组合物及其应用、药盒和包装件
SMT201800318T1 (it) * 2014-01-29 2018-07-17 Ucb Biopharma Sprl Eteroarilammidi come inibitori dell'aggregazione proteica
RU2748294C2 (ru) 2016-06-03 2021-05-21 Зе Трастис Оф Коламбия Юниверсити Ин Зе Сити Оф Нью-Йорк Способ лечения синдрома прадера-вилли
CN108178759B (zh) * 2018-01-05 2020-06-09 上海瑞纷医药科技有限责任公司 一种α-肾上腺素受体拮抗剂的合成方法
CN108498511A (zh) * 2018-04-21 2018-09-07 徐晶 一种治疗膝关节骨性关节炎的药物组合物及其制备方法
WO2020087031A1 (en) 2018-10-26 2020-04-30 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1164198B (it) * 1983-04-28 1987-04-08 Isf Spa Preparazione di un derivato piridazinico farmacologicamente attivo
EP1120418A4 (en) 1998-10-06 2005-01-26 CONDENSED PYRIDAZINE COMPOUNDS, METHOD FOR PREPARING SAME AND USE THEREOF
JP2002205992A (ja) 2000-11-08 2002-07-23 Takeda Chem Ind Ltd 二環式トリアゾロン誘導体およびそれを含有する除草剤
GB0107751D0 (en) * 2001-03-28 2001-05-16 Pfizer Ltd Pharmaceutically active compounds
MXPA04007713A (es) * 2002-02-07 2004-11-10 Pfizer Uso de inhibidores de la fosfodiesterasa tipo 5, tal como sildenafil, en el tratamiento del sindrome de ovario poliquistico.
ATE373660T1 (de) * 2002-03-25 2007-10-15 Merck & Co Inc Heterocyclische beta-aminoverbindungen als inhibitoren der dipeptidylpeptidase zur behandlung bzw. prävention von diabetes
EP1594848A1 (en) 2003-02-19 2005-11-16 Neurogen Corporation Aryl acid pyrimidinyl methyl amides, pyridazinyl methyl amides and related compounds

Also Published As

Publication number Publication date
AR047063A1 (es) 2006-01-04
JP2007514756A (ja) 2007-06-07
TW200530246A (en) 2005-09-16
PE20051047A1 (es) 2005-12-16
CN1918165A (zh) 2007-02-21
ZA200604645B (en) 2007-11-28
US20050192278A1 (en) 2005-09-01
CN1918164A (zh) 2007-02-21
TW200528455A (en) 2005-09-01
WO2005061509A1 (en) 2005-07-07
NO20062689L (no) 2006-09-12
US7037910B2 (en) 2006-05-02
EP1699796A4 (en) 2009-03-04
PE20050756A1 (es) 2005-10-06
EP1699796A1 (en) 2006-09-13
ZA200604778B (en) 2007-12-27
IS8501A (is) 2006-06-08

Similar Documents

Publication Publication Date Title
AR046964A1 (es) Heterociclos azabiciclicos como moduladores de receptor canabinoide, composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades relacionadas con trastornos metabolicos y de la alimentacion.
AR034270A1 (es) 1-aril- o 1-alquilsulfonil-heterociclilbenzazoles como ligandos de 5-hidroxitriptamina-6, un metodo para su preparacion, una composicion farmaceutica y el uso de los mismos para la manufactura de un medicamento
DE60320012D1 (de) Aminoheterocyclen als vr-1 antagonisten zur behandlung von schmerzen
AR036044A1 (es) Compuestos piranoindazoles, composiciones farmaceuticas y su uso para la manufactura de un medicamento para el tratamiento del glaucoma
AR034203A1 (es) Derivados de 1-aril- o 1-alquilsulfonilbenzazol como ligandos de 5-hidroxitriptamina-6, un metodo para su preparacion, composicion farmaceutica y el uso de los mismos para la fabricacion de un medicamento
PA8575401A1 (es) Derivados de heteroarilamida benzocondensada de tienopiridinas utiles como agentes terapeuticos, composiciones farmaceuticas que incluyen a los mismos y metrodos para su uso
UY28692A1 (es) Nuevos derivados de quinolina
AR043998A1 (es) Acidos fenoxiaceticos
AR061643A1 (es) Derivados de ureas de piperidina o pirrolidina, metodos para su preparacion, una composicion farmaceutica que los comprende y el empleo de estos en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por la enzima 11beta-hsd1.
ECSP024393A (es) Derivados biciclicos sustituidos para el tratamiento del crecimiento celular normal
AR037489A1 (es) Quinolinas sustituidas y proceso para su preparacion
UY28526A1 (es) Miméticos de glucocorticoides, métodos de preparación composiciones farmacéuticas y usos de los mismos
AR086357A1 (es) Derivados de indazol sustituidos activos como inhibidores de quinasas
GT199800180A (es) Derivados de la tienopirimidina y de la tienopiridina utiles como agentes anticancerigenos.
AR043180A1 (es) Derivados de heterociclil-3-sulfonilazaindol o -azaindazol como ligandos de 5-hidroxitriptamina-6
AR061015A1 (es) Compuesto y composicion farmaceutica para el tratamiento de un trastorno del sistema nervioso central relacionado con o afectado por el receptor histamina-3 y para la inhibicion del receptor h3 y proceso para la preparacion del compuesto
EA200970928A1 (ru) Антагонисты рецептора гонадотропин-рилизин-фактора и способы их применения
PE20131196A1 (es) Derivados de 6, 7-dihidro-5h-benzo[7]anulenos, metodos para su preparacion, preparaciones farmaceuticas que los contienen y su uso para la preparacion de medicamentos
NO20060682L (no) Indol-6 sulfonamid derivater, deres fremstilling og deres anvendelse 5-HT-6 som modulatorer
AR056197A1 (es) Derivados de 7-metilimidazol[1,2-a]piridin-6-il-8-metil-nonamidas como inhibidores de la renina, composciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para el tratamiento de la hipertension arterial
ATE530187T1 (de) Pharmazeutische zubereitungen mit nk1-rezeptor- antagonisten und natriumkanalblockern
ATE530182T1 (de) Pharmazeutische zubereitungen enthaltend nk1- rezeptoren antagonisten und natriumkanal blockierende verbindungen
AR054786A1 (es) (6-fluor-benzol(1,3) dioxolil)-morfolin-4-il-metanomas, moduladoras del receptor cb1
AR084361A1 (es) Compuestos de aril triazol con actividad antitumoral
ATE447575T1 (de) Selektive spirocyclische glucocorticoid-rezeptor- modulatoren

Legal Events

Date Code Title Description
FC Refusal
FB Suspension of granting procedure